^
Association details:
Biomarker:HER-2 V773A
Cancer:Head and Neck Cancer
Drug:lapatinib (EGFR inhibitor, HER2 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib

Excerpt:
Since levels of up to 1 µM of lapatinib may be achieved in patients, ERBB2-V773A, ERBB2-T862A and ERBB2-N857S (IC90 approximately 0.5 µM) mutations might respond to higher doses of lapatinib,
DOI:
10.1371/journal.pone.0026760